NCT02941913View on ClinicalTrials.gov

Compare Between Two Doses of Palonosetron on the Prevention of Postoperative Nausea and Vomiting in Obese Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

July 31, 2018

Conditions
Postoperative Nausea and Vomiting
Interventions
DRUG

palonosetron

receive a fix dose of 75 μg of palonosetron (group I - GI) and another forty patients will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron (group II - GII).

Trial Locations (1)

20560-120

National Cancer Institute (INCA - HCIII), Rio de Janeiro

All Listed Sponsors
lead

Instituto Nacional de Cancer, Brazil

OTHER_GOV

NCT02941913 - Compare Between Two Doses of Palonosetron on the Prevention of Postoperative Nausea and Vomiting in Obese Patients | Biotech Hunter | Biotech Hunter